Mahkam Zanganeh, serving as Co-Chief Executive Officer, Director, and a ten percent owner of Summit Therapeutics Inc. (NASDAQ:SMMT), executed a substantial acquisition of 3,810,000 shares of common stock on June 12, 2026. The shares were purchased at a price of $13.12 per share, resulting in a total transaction value of approximately $49,987,200. This significant equity acquisition occurs against a backdrop of recent market volatility for Summit Therapeutics, with the stock currently trading at $13.78, a level near the purchase price. The stock has experienced an 11% decline over the past week, moving toward its 52-week low of $12.55.
The acquisition was facilitated indirectly and is categorized as "By Spouse." Following this transaction, Zanganeh's indirect holdings through her spouse have increased to 573,883,879 shares. It is important to note that the reporting person disclaims beneficial ownership of these securities, except to the extent of her pecuniary interest therein, if any. Zanganeh maintains additional indirect stakes in Summit Therapeutics, including 25,824,474 common shares held by the Mahkam Zanganeh Revocable Trust, with Zanganeh serving as Trustee. Furthermore, 76,680 shares are held by an immediate family member, and 10,199,776 shares are held by the Shaun Zanganeh Irrevocable Trust, also with Zanganeh as Trustee. For these indirect holdings, the reporting person disclaims beneficial ownership except to the extent of her pecuniary interest. Zanganeh also holds 31,000 shares directly.
In parallel executive activity, Summit Therapeutics co-chief executive officer Robert Duggan purchased 3.81 million shares at $13.12 per share. This executive buying activity coincides with the company's announcement of a significant $500 million public offering of common stock. Summit Therapeutics plans to sell all shares in this underwritten offering and has granted underwriters a 30-day option to purchase an additional $75 million of shares. In response to the stock offering, shares of Summit Therapeutics experienced a decline.
Analyst reactions to Summit Therapeutics have been mixed. Cantor Fitzgerald reiterated an Overweight rating after a presentation of trial data at a medical conference, indicating optimism about the company's future. Conversely, Bernstein maintained an Underperform rating, citing concerns about the read-through from trial results. These recent developments highlight a period of significant activity and varied analyst opinions for Summit Therapeutics.
Key Points:
- Co-CEO Mahkam Zanganeh acquired 3,810,000 shares at $13.12 per share, totaling ~$49.99 million, increasing indirect holdings through spouse to 573,883,879 shares.
- Summit Therapeutics announced a $500 million public offering with a 30-day option for an additional $75 million, coinciding with co-CEO Robert Duggan's purchase of 3.81 million shares.
- Analyst sentiment is divided, with Cantor Fitzgerald maintaining an Overweight rating based on trial data, while Bernstein holds an Underperform rating due to concerns over trial result implications.
Risks and Uncertainties:
- The significant public offering may lead to further dilution, potentially impacting existing shareholders and contributing to the recent 11% stock decline.
- Divergent analyst ratings highlight uncertainty regarding the commercialization potential of trial results, as evidenced by Bernstein's concerns about the read-through from trial data.
- The stock's proximity to its 52-week low of $12.55 reflects market volatility and potential downward pressure, despite executive buying activity.